HAVCR2 and glioblastoma: Further evaluation of anti-TIM-3 agents (potentially in combination with blockade of other inhibitory receptors such as PD-1 and CTLA-4) in glioblastoma should be strongly encouraged, with the aim that therapeutic regimens centered around blocking TIM-3 function will potentially improve glioblastoma patient survival.